Tofacitinib Citrate (CP-690550): Mechanism, Evidence, and Workflow Integration

Executive Summary: Tofacitinib citrate (CP-690550 citrate) is a potent, selective Janus kinase 3 (JAK3) inhibitor with an IC₅₀ of ~1 nM for JAK3, exhibiting 20-fold and 100-fold lower potency for JAK2 and JAK1, respectively (APExBIO product_spec). It is widely adopted in immune regulation and inflammatory disorder research due to its robust suppression of cytokine signaling in Th1, Th2, and Th17 cell differentiation models (thought_leadership). Tofacitinib citrate reduces endothelial inflammation by inhibiting IL-6 release and modulates adhesion molecule expression in endothelial cells under cytokine stress (ACR Open Rheumatology). APExBIO supplies Tofacitinib citrate (SKU A4135) as a solid form, suitable for dissolution in DMSO or water with specific storage recommendations (product_spec). Comparative data and protocol guidance for immune modulation research are available in recent workflow publications (sumoprotease.com).

Biological Rationale

Janus kinases (JAKs) are non-receptor tyrosine kinases that mediate cytokine receptor signaling, critically regulating lymphocyte proliferation, differentiation, and survival. JAK3 is predominantly expressed in hematopoietic cells and transduces signals from the common gamma-chain (γc) cytokine receptors (e.g., IL-2, IL-4, IL-7, IL-9, IL-15, IL-21) (product_spec). Dysregulation of JAK-STAT signaling is central to the pathogenesis of autoimmune diseases and chronic inflammatory states (ACR Open Rheumatology). Tofacitinib citrate, by selectively inhibiting JAK3, provides a targeted tool to dissect these pathways and model immune cell dynamics in vitro and in vivo.

Mechanism of Action of Tofacitinib citrate (CP-690550 citrate)

Tofacitinib citrate acts as an ATP-competitive inhibitor of JAK3, binding to the kinase domain and preventing phosphorylation events required for STAT activation (product_spec). The compound demonstrates a Ki of 6.5 nM for JAK3, compared to 21.7 nM for JAK2 and 1.6 nM for JAK1, confirming its selectivity profile. In cellular models, Tofacitinib citrate effectively blocks downstream signaling by inhibiting STAT5 phosphorylation in response to γc cytokines (thought_leadership). This results in suppression of key T helper cell subset differentiation: IFN-γ under Th1, IL-4 under Th2, and modulation of IL-17, Foxp3, and IL-10 under Th17 conditions (sumoprotease.com).

Evidence & Benchmarks

• Tofacitinib citrate inhibits JAK3 with an IC₅₀ of ~1 nM in biochemical assays (source: product_spec).
• The compound demonstrates a 20-fold higher IC₅₀ for JAK2 and 100-fold for JAK1, indicating high selectivity (source: product_spec).
• In human endothelial cell models exposed to TNF and IL-17A, Tofacitinib citrate at 1 μM significantly reduced IL-6 release and E-selectin/ICAM-1 induction, but did not prevent thrombomodulin down-regulation (source: ACR Open Rheumatology).
• Typical working concentrations range from 10–100 nM for cell-based assays, with solubility ≥25.22 mg/mL in DMSO and ≥3.4 mg/mL in water with warming/sonication (source: product_spec).
• Tofacitinib citrate does not display direct cytotoxicity to human endothelial cells at 1–10 μM, unlike pan-JAK inhibitors such as fedratinib (source: ACR Open Rheumatology).

This article updates and extends the mechanistic focus of Strategic Advancements with Tofacitinib Citrate by dissecting endothelial and cell-type specific benchmarks. For expanded workflow troubleshooting, see Scenario-Driven Solutions with Tofacitinib citrate, which provides protocol adaptation strategies.

Applications, Limits & Misconceptions

Tofacitinib citrate is employed for:

• Dissecting JAK-STAT signaling in immune regulation research (thought_leadership).
• Modeling lymphocyte proliferation inhibition and T helper cell differentiation in vitro (sumoprotease.com).
• Investigating inflammatory disorder mechanisms, including rheumatoid arthritis and cardiovascular event risk (ACR Open Rheumatology).
• Optimizing assay conditions for immune cell modulation workflows (workflow_recommendation).

Common Pitfalls or Misconceptions

• Tofacitinib citrate is not a pan-JAK inhibitor; its activity is selective for JAK3 and does not fully inhibit JAK1/JAK2 at standard research concentrations (product_spec).
• It does not directly suppress TNF or IL-17A signaling, as these pathways do not utilize the JAK-STAT axis (ACR Open Rheumatology).
• Long-term storage of Tofacitinib citrate stock solutions in DMSO is not recommended due to potential degradation (workflow_recommendation).
• High concentrations (≥10 μM) may alter endothelial adhesion molecule expression, but do not induce apoptosis, unlike some other JAK inhibitors (ACR Open Rheumatology).
• It is insoluble in ethanol and requires specific solvent conditions for dissolution (product_spec).

Workflow Integration & Parameters

Protocol Parameters

• JAK3 kinase inhibition assay | 1 nM IC₅₀ | Biochemical screens | Benchmarks selectivity/potency | product_spec
• Cellular immune modulation | 10–100 nM | T/B cell cultures | Effective for Th1/Th2/Th17 modulation | workflow_recommendation
• Solubility in DMSO | ≥25.22 mg/mL | Stock solution prep | Ensures reproducibility in cell-based assays | product_spec
• Solubility in water (ultrasonication) | ≥3.4 mg/mL | Aqueous applications | For in vivo/intracellular delivery | product_spec
• Storage of solid | −20°C | All research uses | Preserves integrity long-term | product_spec
• Storage of DMSO solution | <−20°C, several months | Short-term/medium-term | Avoids degradation; not for long-term | workflow_recommendation

For scenario-based troubleshooting and advanced workflow adaptations, the article Scenario-Driven Solutions with Tofacitinib citrate offers practical guidance beyond standard protocol sheets.

Conclusion & Outlook

Tofacitinib citrate (CP-690550 citrate) remains a cornerstone reagent for dissecting JAK-STAT signaling, immune cell function, and inflammation in preclinical models. Its nanomolar potency and JAK3 selectivity enable precise experimental modulation, with a robust record of reliability in published endothelial and immune cell studies (ACR Open Rheumatology). However, users must observe solubility and storage constraints to maximize reproducibility. Future research will further clarify the differential vascular and immune consequences of selective JAK inhibition, as highlighted in recent mechanistic and cardiovascular safety studies. APExBIO continues to provide high-purity Tofacitinib citrate (A4135), supporting the evolving needs of immune regulation and inflammatory disorder research (APExBIO product page).